Clinical Laserthermia Systems Introduces MRI-Guided Laser Ablation System for Soft Tissue Treatment

Clinical Laserthermia Systems Americas Inc. (CLS), a subsidiary of CLS AB in Lund, Sweden, has announced the availability of its TRANBERG |Thermal Therapy System, including a mobile laser system and single-use products for high precision, image-guided, laser ablation of soft tissue. This advanced focal therapy provided by the TRANBERG System is designed to reduce morbidity and improve clinical outcomes within interventional oncology and urology. The system is currently in use at numerous hospitals in the United States, Sweden, and other European countries.
 
U.S. customers for CLS include the University of Texas Medical Branch, the Laser Prostate Centers of America, and Desert Medical Imaging. CLS received U.S. Food and Drug Administration (FDA) clearance for its single-use TRANBERG|Laser Applicator Non-cooled diffusor fiber in early 2017.
 
“We are very pleased by the enthusiastic feedback given to us on the use of our products and the positive patient results being reported by our prominent partners and physicians,” said Dan Mogren, chief commercial officer of CLS.  “We are now beginning to see new and larger orders as well as repeat orders coming from the market, which is an important sign of acceptance.”
 
The TRANBERG |Thermal Therapy System has been developed for image guided high precision soft tissue thermal therapy and ablation procedures. The system can be configured for magnetic resonance (MR) or computed tomography (CT)/U.S.-guided procedures using tissue temperature feedback for precise therapy and ablation control. It includes a desktop mobile laser unit, new non-cooled laser applicators, external tissue temperature probe sensors, and procedure specific accessories.
 
The applicator portfolio includes 3m and 12m non-cooled 16 Gauge laser applicators allowing for almost any type of image guidance, including MR. With CLS’ unique diffusing fiber technology, heat distribution in tissue is optimized and the need for external cooling is eliminated. Features also aimed at improving workflow and shortening procedure time.
 
For high precision during CT/U.S.-guided procedures, high accuracy temperature probes can be used for monitoring and controlling tissue temperatures in and around the target tissue.
 
Clinical Laserthermia Systems AB develops and sells the TRANBERG |Thermal Therapy System including its specially-designed sterile disposable products for treatment of soft tissue such as cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT. The company, which has a subsidiary in Boston, Mass., is listed on Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance.
 
The TRANBERG |Thermal Therapy System has not yet received market clearance for immune stimulating interstitial laser thermotherapy (imILT) by the FDA.